ContactContact

Successful in a challenging environment

Jörg Kneubühler, Chairman of the Board of Directors, Jean-Claude Clémençon, CEO
Jörg Kneubühler, Chairman of the Board of Directors, Jean-Claude Clémençon, CEO

Dear Shareholders,

Ladies and Gentlemen,

2018 was a challenging year for the Swiss healthcare market. The higher than originally announced drug price reductions by the authorities, ongoing shopping tourism and the growing importance of online sales in retail had a major influence. These were accompanied by discussions at political level, the implementation of which will occupy us in the future.

Thanks to our focused corporate strategy, targeted acquisitions, the launch of new products, services and innovations as well as measures to improve efficiency, we even surpassed our announced results for 2018. Accordingly, the Board of Directors will propose a 3% higher dividend than the prior year of CHF 1.70 per share to the 2019 Annual General Meeting (previous year: CHF 1.65).

Key figures 2018

  • Net sales: CHF 3,165.0 million
  • EBIT: CHF 154.1 million 1)
  • Net profit: CHF 124.7 million 1)
  • Investments: CHF 50.0 million
  • Employees: 6,580 (5,106 full-time equivalents)

    1) Adjusted

Bern, 12 March 2019

"It is important to be in tune with customers both offline and online today. Doing so enables us to serve customers where it is most convenient for them."

 
 

+9.1%

EBIT growth (on a comparable basis)

Contact

Galenica Ltd.

Untermattweg 8
3027 Bern

Tel. +41 58 852 81 11
Fax +41 58 852 81 12